Ethical and scientific concerns regarding the use of human fetal bones in the SCID-hu model of primary human myeloma prompted us to develop a novel system that uses rabbit bones implanted subcutaneously in unconditioned SCID mice. Immunohistochemical analysis of the implanted bone revealed that the majority of bone marrow (BM) microenvironment cells such as blood vessels, osteoclasts and osteoblasts were of rabbit origin. The implanted bones were directly injected with myeloma cells from 28 patients. Successful engraftment of unseparated BM cells from 85% of patients and CD138-selected myeloma plasma cells from 81% of patients led to the production of patients' M-protein isotypes and typical myeloma manifestations (osteolytic bone lesions and angiogenesis of rabbit origin). Myeloma cells grew exclusively in the rabbit bone, but were able to metastasize into another bone at a remote site in the same mouse. Cells from patients with extramedullary disease also grew along the outer surface of the rabbit bones. This demonstrates the ability of SCID-rab model, marked by a nonmyelomatous, nonhuman, and nonfetal microenvironment, to support the growth of CD138-expressing myeloma cells. This system can now be widely used to study the biology of myeloma and its manifestations and to develop novel therapeutic approaches for this disease.
Introduction
Multiple myeloma (MM) is characterized by accumulation of low proliferative CD138 (syndican-1)-expressing malignant plasma cells (PCs) in the hematopoietic bone marrow (BM). In advanced stage of the disease, myeloma PCs often disseminate to extramedullary sites. Development of an adequate experimental model for primary myeloma was needed to study critical biological issues, including the role of the microenvironment in disease progression, identification of the proliferative compartment or the myeloma 'stem cell,' and unraveling of the importance of various genetic changes in myeloma pathogenesis.
Although murine models of myeloma have been developed and contribute to our understanding of certain aspects of myeloma biology, they involve either induced tumors associated with an incompatible typical myeloma growth pattern 1, 2 or spontaneously originating tumors in a single aging C57BL mouse, which are transferred to syngeneic recipients. 3, 4 These models thus do not resemble the heterogeneous characteristics of human myeloma as seen in different patients.
Primary myeloma cells from most patients do not grow in severe combined immunodeficiency (SCID) mice. Previous studies demonstrated the ability of mobilized blood mononucleate cells or CD34-enriched cells from patients with advanced disease, injected intracardially, to produce myeloma in irradiated nonobese diabetic/SCID (NOD/SCID) mice. [5] [6] [7] However, the source of the supportive microenvironmental elements or the growth potential of the recognizable myeloma PCs were not studied in these reports. Recent report demonstrated the ability of subpopulation of CD138
À , but not CD138 þ tumor cells, isolated from four patients and injected intravenously, to grow in NOD/SCID mice and suggested that myeloma 'stem cells' are CD138 À B cells. 8 Reproducible growth of primary human myeloma has been demonstrated only in SCID-hu mice, in which tumor cells grow dependently in and interact with a human microenvironment provided by subcutaneous implantation of human fetal bones. We have exploited this model, which was initially used to study the growth of primary leukemic cells 9 and the homing of myeloma cell lines, 10 to study primary human myeloma. BM cells or purified myeloma PCs from a majority of patients with myeloma were successfully engrafted in this system, producing typical myeloma manifestations such as increased osteoclastic activity, induction of severe lytic bone disease, and stimulation of angiogenesis. 11 Although this model has helped shed light on the crucial aspects of myeloma biology, [12] [13] [14] [15] the use of fetal bones has limited broad employment of this model by others because of ethical reasons, and raised scientific concerns whether embryonic, stem cellenriched bone is an adequate, 'normal' microenvironment for growing primary myeloma.
As rabbits are phylogenetically closer to primates than are rodents, 16 we thought of replacing the human fetal bone with a rabbit's bone. Here we demonstrated the ability of rabbit BM microenvironment to attract and support sustained growth of primary CD138-selected myeloma PCs from 481% of patients. As in most patients, growth of myeloma cells is restricted to the hematopoietic BM and associated with typical myeloma manifestations, such as increased osteoclastic activity and stimulation of neovascularization.
Materials and methods

Myeloma cells
Myeloma cells were obtained from heparinized BM aspirates from 28 patients with active myeloma during scheduled clinic visits. Signed Institutional Review Board-approved informed consent forms are kept on record. Pertinent patient information is provided in Table 1 . The BM samples were separated by density centrifugation using Ficoll-Paque (specific gravity, 1.077 g/ml; Amersham Biosciences Corp., Piscataway, NJ, USA), and the proportion of myeloma PCs in the light-density cell fractions was determined by CD38/CD45 flow cytometry. In 16 experiments, PCs were isolated by CD138 immunomagnetic bead selection and the autoMACs automated separation system (Miltenyi-Biotec, Auburn, CA, USA). PC purity was determined by CD38/CD45 flow cytometry to be routinely X95% (Figure 1) .
Construction of the 'SCID-rab' model
CB.17/Icr-SCID mice (6-8-week old) were obtained from Harlan Sprague Dawley (Indianapolis, IN, USA) and pregnant New Zealand rabbits from Myrtle Rabbitry (Thompson Station, TN, USA). The mice, female rabbits and their newborn were housed and monitored in our animal facility. The Institutional Animal Care and Use Committee approved all experimental procedures and protocols. The 3-4-week-old rabbits were deeply anesthetized with a high dose of pentobarbital sodium and euthanized by cervical dislocation. The femora and tibiae were cut into two pieces, with the proximal and distal ends kept closed, while the vertebrae were cut into small fragments (1 Â 2 cm 2 ). For bone implantation, the right or left side of the SCID mouse was rinsed with alcohol and blotted with sterile gauze. The bone was inserted subcutaneously through a small (5 mm) incision. The incision was then closed with sterile surgical staples, and engraftment of the bones was allowed to take place for 6-8 weeks. In some experimental mice, two bones were simultaneously implanted contralaterally in the same mouse. For each experiment, 10-50 Â 10 6 unseparated myeloma BM cells containing 1778% PCs or 3.371.6 Â 10 6 purified PCs in 50 ml of phosphate-buffered saline (PBS) were injected directly into the implanted rabbit bone. At least two mice were used for each experiment. Mice Purity level and phenotype of CD138-selected myeloma PCs. PCs isolated by CD138 immunomagnetic bead selection were stained for CD38/CD45 and CD19/CD34. A representative sample demonstrating a high purity level of mature myeloma PC expressing CD38 high CD45
low (left panel), but not CD19 and CD34 (right panel). Growth of CD138-selected myeloma PCs from 16 patients was examined in the SCID-rab model. In vivo model for primary human myeloma K Yata and S Yaccoby were periodically bled from the tail vein to measure changes in levels of circulating human immunoglobulin (Ig) of the Mprotein isotype.
Determination of human Ig levels
Levels of human IgG, IgA, and k and l light chains were determined by ELISA as described. 11, 12 At the end of each experiment, all samples from each experiment were analyzed in the same assay in order to preclude interassay variability.
Radiographic evaluation
Mice were anesthetized with ketamine plus xylazine. Radiographs taken with an AXR Minishot-100 beryllium source instrument (Associated X-Ray Imaging Corp., Haverhill, MA, USA) used a 10-s exposure at 40 kV.
Immunohistochemistry and histochemistry
Mice were deeply anesthetized with ketamine plus xylazine and euthanized by cervical dislocation. Tissues (bones, spleen, and liver) were fixed in 10% phosphate-buffered formalin for 24 h. Rabbit and murine bones were further decalcified with 10% (w/v) ethylenediaminetetraacetic acid (EDTA), pH 7.0. The tissues and bones were embedded in paraffin for sectioning. Sections (5 mm) were deparaffinized in xylene, rehydrated with ethanol, rinsed in PBS, and stained as previously described. 11, 12, 14 After antigen retrieval, sections were reacted with antibodies to human Ig and rabbit macrophage antigen (RAM-11) (DAKO, Carpinteria, CA, USA), von Willebrand factor/factor VIII (Binding Site, Birmingham, UK), rabbit macrophage antigen (Cymbus Biotechnology, Chandlers Ford, UK), rabbit CD141 (Antigenix America, Huntington State, NY, USA), vascular endothelial growth factor (VEGF; Neo Markers, Fremont, CA, USA), and mouse CD34 (Cell Sciences, Canton, MA, USA). The assays were completed with the use of Vector's immunoperoxidase kit (Burlingame, CA, USA). Sections were counterstained with hematoxylin. According to the manufacturers, the RAM-11 and rabbit macrophage antibodies are rabbit specific, antimurine CD34 is mouse specific, CD141 and VEGF antibodies crossreact with human and rabbit but not with mouse tissues, and antifactor VIII antibody crossreacts with the three species. Tartrateresistant acid phosphatase (TRAP) staining of deparaffinized bone sections was performed with an acid phosphatase kit (Sigma, St Louis, MO, USA). Factor VIII-reactive microvessels and TRAP-positive multinucleated osteoclasts in four nonoverlapping, millimeter-square areas were counted. All values were expressed as mean7s.e.m. and Student's t-test was used to test differences between myelomatous and nonmyelomatous rabbit bones.
Screening for Epstein-Barr virus (EBV)
Myeloma cells recovered from tumor-engrafted mice were analyzed for the presence of EBV sequences and transcripts by polymerase chain reaction (PCR) and reverse transcriptase (RT)-PCR. 17 All tested samples were negative.
Results
Growth of BM and purified myeloma PCs from patients with myeloma in the SCID-rab model
In our novel system, named the 'SCID-rab,' femora, tibiae, and vertebrae from young rabbits were implanted subcutaneously in unconditioned SCID mice, and engraftment was allowed to take place for 6-8 weeks before the inoculation of tumor cells. Morphologically, all the implanted rabbit bones were viable, had no visible necrosis, and were characterized by a high proportion of adipocytes, resembling adult BM. The implanted bones also had reduced hematopoietic activity, compared with preimplanted bones. Nevertheless, BM elements such as osteoclasts, osteogenic cells (osteoblasts, osteocytes), blood vessels, and other stromal cells were well maintained in the implanted bones (Figure 2a) . Antirabbit VEGF and macrophage antibodies used for immunohistochemical staining reacted with these microenvironment BM cells in the implanted bone but not In (Figure 2b-e) . Myeloma cells from 28 patients, including newly diagnosed and previously treated patients at various clinical stages, were assessed (Table 1) . Myelomatous BM cells from 13 patients containing 1778% PCs and purified myeloma PCs from 16 patients were studied in the SCID-rab model (Table 1) . Myeloma developed in 11 myeloma BM (B85%) and 13 myeloma PC (81%) samples, as indicated by increased serum levels of monotypic human Ig. Levels of human Ig, although varied among patients' cells, were detected as early as 1 week after inoculation and reached 135771690 mg/ml Ig light chain and 212372673 mg/ml Ig heavy chain 5-20 weeks later, at which time the mice were euthanized for further examination. Examples of three experiments are shown in Figure 3 . Rabbit femora, tibiae, and vertebrae similarly supported tumor growth in this model. Myeloma PCs from four patients injected into the SCID-rab and the SCID-hu mice had similar growth rate and pattern, and produced typical disease manifestations in both systems (Figure 3d) .
In all experiments, circulating human Ig was identical to patients' M-protein isotype in terms of both heavy and light Ig chains. Myeloma cells recovered from the implanted bones were all negative for the presence of EBV, as ascertained by PCR and RT-PCR (data not shown). In five experiments, mice had no detectable human Ig levels at 13-24 weeks post-inoculation, and myeloma cells could not be detected by histologic or immunohistochemical examinations of the rabbit bones. Myeloma cells that did not grow were taken from both newly and previously treated patients and were not restricted to a certain clinical stage of specific M-protein isotype (Table 1) .
In one experiment (patient #28), 1 Â 10 5 , 5 Â 10 5 , and 1 Â 10 6 CD138-selected myeloma PCs were each injected into three mice. Myeloma growth was detected in three out of three mice injected with 5 Â 10 5 and 1 Â 10 6 cells, but not in any mice injected with 1 Â 10 5 myeloma PCs (Figure 3c ). In all cases, human myeloma cells were not detected in any of the examined murine compartments (blood, BM, spleen, liver, peritoneum), as determined by immunohistochemistry for cytoplasmic Ig and by human CD38/CD45 flow cytometry (Figure 4) . Flow cytometry analysis of cells extracted from myelomatous rabbit bones revealed a high proportion of CD45 À CD38 þ myeloma PCs. Further histologic examination of decalcified myelomatous rabbit bones revealed infiltration of myeloma cells expressing Ig of the M-protein isotype only (Figure 4) . Moreover, in four experiments, myeloma PCs were sequentially transferred and successfully engrafted in secondary and tertiary hosts, which confirmed the sustained proliferative potential of myeloma PCs (data not shown).
Growth of primary human myeloma in SCID-rab mice is associated with typical disease manifestations
Growth of myeloma cells from all patients was associated with the development of different degrees of bone disease, as assessed by radiographs (Figure 5a, b) . In some cases, the myelomatous rabbit bone had almost completely disintegrated. Decalcified bone sections stained for TRAP revealed increased number of osteoclasts in areas infiltrated by tumor cells (Figures  5d and 6 ). These osteoclasts were of rabbit origin, as confirmed by their reactivity with anti-rabbit macrophage antibody (Figure 5e ).
Induction of neomicrovessels was apparent in areas infiltrated by tumor cells and in fibrotic areas, as determined by staining for von Willebrand factor/factor VIII (Figures 5f and 6 ) and In vivo model for primary human myeloma K Yata and S Yaccoby CD141 (Figure 5g ). The antifactor VIII murine monoclonal antibody used in this study crossreacts with human, rabbit, and murine cells, whereas anti-CD141 crossreacts with rabbit and human cells only. Very few stained positive for factor VIII and CD141 in nonmyelomatous implanted bones and none of the vessels were reacted with anti-human CD34 (data not shown). However, while increased numbers of CD141-and factor VIIIreactive vascular endothelial cells were observed in all myelomatous bones, including those engrafted with highly purified myeloma PCs, only few vessels reacted to monoclonal antibody for murine CD34, indicating that the majority of tumor-associated microvessels were of rabbit origin. 
In vivo model for primary human myeloma K Yata and S Yaccoby
The SCID-rab model can be used to study differences between medullary and extramedullary disease and homing mechanisms of myeloma cells
In all experiments, myeloma cells were not detected in any murine organs. Whereas myeloma cells from most patients grew exclusively in the rabbit BM microenvironment (medullary myeloma), cells from patients with extramedullary disease (patients 13, 14, 16, and 18; Table 1 ) also grew along the outer surface of the rabbit bones, akin to their growth pattern in humans (Figure 5b, c) . Indeed, rabbit microenvironment cells, such as vascular endothelial cells and other stromal cells, were detected in extramedullary tumors (data not shown), indicating that the rabbit microenvironment was still required for their growth and survival. In three experiments (patients 13, 14, and 18), SCID mice were implanted contralaterally with two rabbit bones, and myeloma PCs were injected into only one bone. In two (patients 14 and 18) of the three experiments, although the myeloma cells disseminated to the second bone, they were not detected in the murine tissues (Figure 7 ). This finding emphasizes the ability of the rabbit BM microenvironment to attract and support myeloma cell growth.
Discussion
The SCID-rab model is a novel in vivo system in which a nonmyelomatous, nonhuman, and nonfetal microenvironment in the form of a rabbit bone has demonstrated the ability to support sustained growth of primary human myeloma PCs from a majority of patients. To our knowledge, this is the first report demonstrating the potential of isolated primary CD138-enriched PCs to proliferate, propagate, and produce typical myeloma manifestations in vivo. These results are in contrast to recent study showing the inability of purified CD138-expressing PCs to grow in NOD/SCID mice, 8 but in accord with previous reports demonstrating the ability of human 12 and murine 18, 19 mature CD45
À myeloma PCs to grow and manifest in a nonmyelomatous environment.
Rabbit hematopoietic and nonhematopoietic elements were maintained in the implanted bones and supported the growth of myeloma cells taken from either unseparated BM cells or CD138-enriched myeloma PCs from 23 of 28 newly diagnosed and previously treated patients at different clinical stages. In all experiments, myeloma cells produced monoclonal immunoglobulins of the M-protein isotype, with no exceptions.
Similar to the SCID-hu model, myeloma cells from all patients with medullary myeloma grew restrictively in the rabbit bone, and through interaction with the rabbit BM microenvironment, they produced typical disease manifestations, such as induction of severe lytic bone disease and angiogenesis. Tumor cells taken from patients with extramedullary disease (PC leukemia) started to grow in the BM, but then spread out and disseminated also along the outer surface of the rabbit bone. Thus, while these cells were independent of the BM microenvironment, other detectable rabbit stromal elements, such as vascular endothelial cells, were required for extramedullary growth. Furthermore, the tumor cells disseminated only from one rabbit bone to another, demonstrating the ability of the rabbit bone microenvironment to attract myeloma cells and sustain their growth.
The supporting cells in the rabbit bone of myelomatous mice were of rabbit origin, as determined immunohistochemically by their reactivity to antirabbit antibodies against various markers. Visible accessory cells seen in myelomatous bones were adipocytes, osteoclasts, osteoblasts, vascular endothelial cells, and occasionally fibroblasts. As demonstrated in other experimental models 11, 15, [20] [21] [22] and in clinical observations, 23, 24 myeloma growth in the SCID-rab was associated with increased numbers of osteoclasts and tumor-associated microvessels. Reproducible growth of primary human myeloma has been demonstrated only in the SCID-hu and our novel model. [11] [12] [13] [14] [15] Another potential system is the NOD/SCID mouse, but a recent report examined the growth of CD138 À myeloma cells from only four patients and did not study typical disease manifestations in these mice. 8 Although percent engraftment, growth patterns, and myeloma manifestations are similar in the SCIDrab and SCID-hu mice, both systems can be successfully exploited to study myeloma-microenvironment interactions, but the choice of system should be based on the research goal. Growth of myeloma cells in the rabbit bone is associated with increased numbers of multinucleate osteoclasts and microvessel density (MVD). Values are mean7s.e.m. for nonmyelomatous (n ¼ 5) and myelomatous (N ¼ 10) bones. Numbers of osteoclasts and MVD were significantly higher in myelomatous rabbit bones.
Figure 7
Primary myeloma cells exclusively home to rabbit bone microenvironment in the SCID-rab model. A SCID mouse was implanted with two contralaterally placed rabbit bones. CD138-selected myeloma PCs from patient #18 (Table 1) were inoculated into the human bone on the right flank of one mouse (primary bone). Radiographs of (a, b) the primary and (c, d) the remote bones before and 12 weeks after injection of tumor cells show severe bone resorption in both the primary (b) and the remote (d) bones. (e) Histologic section of the remote rabbit bone, stained for H&E, confirmed the infiltration of myeloma cells. (f) BM cells extracted from the murine femora and analyzed for human CD45/CD38 revealed no infiltration of myeloma cells.
In vivo model for primary human myeloma K Yata and S Yaccoby
For instance, the SCID-hu system is favored for studying the interaction of tumor cells with human stroma elements, but it cannot be appropriately applied for studying myeloma-stem cell interactions. The stem cell-enriched fetal microenvironment might not provide accurate results on whether myelomaassociated microvessels emerge from angiogenesis or vasculogenesis. In another example, approaches to increase bone formation in myelomatous bones may not be useful when using the SCID-hu system because fetal BM contains a high pool of osteoblast precursors that may not resemble the BM in elderly myeloma patients. In these cases, the SCID-rab model will be advantageous. The SCID-rab system also allows to trace and identify human cells (malignant and nonmalignant) injected into the rabbit bone based on species specificity, and can potentially be used to study the effect of genetically manipulated rabbit bones on growth of human myeloma. In summary, our novel in vivo system provides a hospitable environment for the growth of human primary myeloma cells. Tumor growth patterns and typical manifestations in the model mimic clinical myeloma. The SCID-rab model can now be widely used to study the biology of myeloma and its manifestations and to develop novel therapeutic approaches to this disease.
